NDAINJECTIONINJECTABLE
Approved
Dec 1999
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
2
Data completeness
2/8 — Basic
Drug data last refreshed 17h ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
OPTIMARK (gadoversetamide) is a gadolinium-based contrast agent administered via injection for magnetic resonance imaging (MRI) enhancement. It is a small molecule contrast agent that accumulates in target tissues to improve visualization during MRI procedures. The drug facilitates diagnostic imaging by enhancing contrast between normal and abnormal tissue.
LOE Approaching
With LOE approaching and limited current market data, the brand team is likely in defensive positioning with focus on retention strategies rather than growth initiatives.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (2)
Evaluation of Nephrogenic Systemic Fibrosis (NSF) in Patients With Chronic Kidney Disease Following OptiMARK Injection
Started Feb 2009
0Nephrogenic Systemic FibrosisRenal Insufficiency
Study to Evaluate the Safety, Efficacy and Pharmacokinetics of Optimark (Gadoversetamide) in Pediatric Patients
Started May 2002
100 enrolled
Pathological Processes
Career Relevance
Working on OPTIMARK offers stability in a mature diagnostic product with established market presence, but limited growth trajectory or innovation opportunities. Career advancement may be constrained by the product's LOE approaching status, making this role better suited for individuals seeking operational excellence or diagnostic imaging expertise rather than dynamic brand building.
Worked on OPTIMARK at Guerbet? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.